Clinical trials: Demyelinating Disorder
Multiple Sclerosis
Prospective Randomized Endovascular Therapy in Multiple Sclerosis
1. To assess the safety of endovascular therapy (balloon angioplasty) for venous stenoses in MS patients with CCSVI as documented by sonographic (extracranial echocolor-Doppler (ECD) and transcranial color Doppler (TCD) 2.
- Trial name
- PREMiSe (NCT05380362)
- Testing
- Venous Angioplasty
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University at Buffalo
Multiple Sclerosis, Spasticity
Developing and Testing a Comprehensive MS Spasticity Management Program
This is a study to determine the impact of education and specific lower extremity stretches for MS-related spasticity. The study will evaluate the acceptance and efficacy of education and stretching using a randomized controlled…
- Trial name
- NCT02170779
- Testing
- Spasticity: Take Control, Usual care
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- VA Office of Research and Development
Multiple Sclerosis
Short-term B-cell Depletion in Relapsing Multiple Sclerosis
Several disease-modifying therapies (DMTs) have been shown to be effective in reducing the disease activity in patients with relapsing forms of multiple sclerosis (MS) but these treatments, often need to be used continuously for…
- Trial name
- NCT03853746
- Testing
- Ocrelizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Multiple Sclerosis
MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV
MAIN STUDY: The purpose of this study is to determine if teriflunomide will be safe and effective to prevent relapses in patients with relapsing types of MS when switching from natalizumab to teriflunomide in patients at risk for…
- Trial name
- NCT01970410
- Testing
- teriflunomide
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- Providence Health & Services
Multiple Sclerosis
Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis
Medical marijuana is commonly prescribed people with Multiple Sclerosis (MS) for symptom, e.g. spasticity and pain, management. Unfortunately not much is known about its effects outside the treatment for these 2 symptoms.
- Trial name
- NCT02898974
- Testing
- Medical Marijuana
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Colorado State University
Multiple Sclerosis
Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
Background: Secondary-progressive multiple sclerosis (SP-MS) is the chronic phase of multiple sclerosis (MS). The majority of people who have relapsing-remitting MS eventually develop SP-MS.
- Trial name
- NCT01212094
- Testing
- Rituximab, normal saline
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Multiple Sclerosis, Cognitive Impairment
Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment
This study evaluated the efficacy and safety of 10 cm² rivastigmine patch vs. placebo in cognitively impaired Multiple Sclerosis (MS) patients.
- Trial name
- EXCITING (NCT00881205)
- Testing
- Rivastigmine transdermal patch
- Where
- 49 sites in Germany
- Volunteers
- 86 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis
This was a Phase II, randomized, open-label, rater-blinded, three-arm study comparing two different doses of alemtuzumab (Lemtrada™) and one dose of subcutaneous (SC) interferon beta-1a (Rebif®) in participants with early, active…
- Trial name
- NCT00050778
- Testing
- Interferon beta-1a, Alemtuzumab 12 mg, Alemtuzumab 24 mg
- Where
- 49 sites in United States, Croatia and 3 more
- Volunteers
- 334 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Sclerosis
Neuroprotection With Riluzole Patients With Early Multiple Sclerosis
This is a double blind, randomized, parallel group design placebo-controlled mono-center study. Patients will be evaluated within twelve months of CIS onset.
- Trial name
- NCT00501943
- Testing
- Avonex (Interferon beta 1a), Riluzole
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of California, San Francisco
Relapsing Multiple Sclerosis
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis
To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis
- Trial name
- ASCLEPIOS I (NCT02792218)
- Testing
- Ofatumumab subcutaneous injection, Teriflunomide capsule
- Where
- 166 sites in United States, Argentina and 27 more
- Volunteers
- 930 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Remitting Multiple Sclerosis
Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis
The objectives of the study are: comparison of the incidence and time course of the development of neutralizing antibodies (NAbs) to Rebif after 48 weeks of therapy, to historical data from Serono clinical trial databases to…
- Trial name
- NCT00367484
- Testing
- Rebif® (clone 484-39)
- Volunteers
- 460 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Primary Progressive Multiple Sclerosis
Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)
Background: Multiple sclerosis (MS) is an inflammatory disorder of the central nervous system that progressively weakens and destroys the pathways of the nervous system.
- Trial name
- IPPoMS (NCT00950248)
- Testing
- Idebenone
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Primary Progressive Multiple Sclerosis
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
This Phase 2 study is intended to serve as a proof of concept for potential treatment with laquinimod in patients with PPMS. The study is also aimed at evaluating 2 doses of laquinimod in this population.
- Trial name
- ARPEGGIO (NCT02284568)
- Testing
- Laquinimod
- Where
- 99 sites in United States, Canada and 8 more
- Volunteers
- 374 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis
Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks
This study will evaluate if patients who had a serious cardiovascular event upon initiation of fingolimod are at risk to delevop long term other cardiovascular events
- Trial name
- NCT02232061
- Testing
- Fingolimod
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Remitting Multiple Sclerosis
Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC)
A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient Outcomes, Safety and Tolerability of (fingolimod) 0.5 mg/day in Patients with Relapsing Remitting Multiple Sclerosis who are candidates…
- Trial name
- EPOC (NCT01534182)
- Testing
- Fingolimod, Interferon beta - 1a (IFN), Glatiramer acetate (GA)
- Where
- 26 sites in Russia
- Volunteers
- 298 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
The primary objective of the study is to evaluate the long-term safety of BG00012 in subjects who completed Study 109MS202 (NCT02410200).
- Trial name
- NCT02555215
- Testing
- dimethyl fumarate
- Where
- 12 sites in United States, Belgium and 8 more
- Volunteers
- 20 people
- Sponsor
- Biogen
Multiple Sclerosis
RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate
This is a Phase IV, prospective, open-label, multi-center trial to assess the treatment satisfaction in patients with relapsing forms of Multiple Sclerosis (MS) who are currently being treated with, but are considering…
- Trial name
- RESOunD (NCT02117050)
- Testing
- Rebif®
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- EMD Serono
Multiple Sclerosis
Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients
This study evaluates the effect of adding fish oil to Fingolimod on some serum cytokines in patients with Relapsing-Remitting Multiple Sclerosis.
- Trial name
- NCT02939079
- Testing
- Fingolimod, Fish Oil
- Volunteers
- 50 people
- Sponsor
- Isfahan University of Medical Sciences
Multiple Sclerosis
Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS
The purpose of this study is to find out if cannabis-based medicine compared to a dummy medicine (placebo that contains no active ingredient) can help the central neuropathic pain patients experience as a result of multiple…
- Trial name
- NCT00391079
- Testing
- Sativex
- Where
- 6 sites in Canada
- Volunteers
- 339 people
- Sponsor
- GW Pharmaceuticals Ltd
Chronic Inflammatory Demyelinating Polyneuropathy
Subcutaneous Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The investigators are using self administered subcutaneous immunoglobulin (SCIG) in patients with CIDP who require Intravenous immunoglobulin (IVIG). Safety, efficacy, and patient satisfaction will be examined.
- Trial name
- SCIG (NCT02465359)
- Testing
- Immune Globulin Subcutaneous (Human)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of South Florida